Investors One-year Losses Continue as Northeast Pharmaceutical Group (SZSE:000597) Dips a Further 6.9% This Week, Earnings Continue to Decline
Investors One-year Losses Continue as Northeast Pharmaceutical Group (SZSE:000597) Dips a Further 6.9% This Week, Earnings Continue to Decline
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. For example, the Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597) share price is down 22% in the last year. That contrasts poorly with the market decline of 10%. However, the longer term returns haven't been so bad, with the stock down 17% in the last three years. Even worse, it's down 19% in about a month, which isn't fun at all.
passively investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk underperformance. For example, Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597) 股票在过去一年中下跌了22%。这与市场下跌10%形成了鲜明的对比。然而,长期回报表现并不差,股票过去三年下跌了17%。更糟糕的是,一个月内下跌了19%,这一点都不好玩。
Given the past week has been tough on shareholders, let's investigate the fundamentals and see what we can learn.
考虑到过去一周对股东来说是艰难的,让我们调查一下基本面并看看我们能学到什么。
To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
引用巴菲特的话顺便说一下,“船只将环游世界,但支持地球平面学会的人将大有可为。 在市场上,价格和价值之间将继续存在巨大的差异...”通过比较EPS和股价变化,我们可以了解到投资者对公司的态度随时间的变化程度。
Unfortunately Northeast Pharmaceutical Group reported an EPS drop of 2.6% for the last year. The share price decline of 22% is actually more than the EPS drop. So it seems the market was too confident about the business, a year ago.
不幸的是,东北制药报告了去年的每股收益下降了2.6%。股票下跌了22%,实际上比每股收益下跌更多。因此,似乎市场对公司业务前景过于乐观了一年。
The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).
下图显示了EPS随时间的变化情况(如果您单击该图像,则可以查看更多详细信息)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240607/0-6e7af1de0abdf88c5755474fe126c647-0-bb7147baa27a0d8150c77b28803cb2e5.png/big)
This free interactive report on Northeast Pharmaceutical Group's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.
如果您想进一步调查股票,东北制药的收益,营业收入和现金流免费互动报告是一个很好的起点。
A Different Perspective
不同的观点
While the broader market lost about 10% in the twelve months, Northeast Pharmaceutical Group shareholders did even worse, losing 20% (even including dividends). Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 3% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Northeast Pharmaceutical Group has 2 warning signs we think you should be aware of.
虽然整个市场在过去的十二个月中损失了约10%,但东北制药的股东甚至做得更差,失去了20%(包括股息)。也就是说,在下跌的市场中,一些股票被超卖是不可避免的,关键是要关注基本面的发展。遗憾的是,去年的表现加剧了糟糕的局面,股东面临了每年总亏损3%。一般来说,长期股价走弱可能是一个不好的迹象,尽管逆势投资者可能希望研究这只股票以期待逆转。虽然考虑市场条件可能对股价产生的不同影响非常值得,但其他因素更为重要。例如承担风险 - 东北制药有2个警告信号,我们认为您应该注意这些。
Of course Northeast Pharmaceutical Group may not be the best stock to buy. So you may wish to see this free collection of growth stocks.
当然,东北制药可能不是最好的购买股票。因此,您可能希望查看这些强劲增长股票的免费收藏。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。